1. Home
  2. PLBL vs TVTX Comparison

PLBL vs TVTX Comparison

Compare PLBL & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBL

Polibeli Group Ltd Class A Ordinary Shares

N/A

Current Price

$7.14

Market Cap

3.0B

Sector

N/A

ML Signal

N/A

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$40.07

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBL
TVTX
Founded
2021
N/A
Country
Indonesia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.8B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PLBL
TVTX
Price
$7.14
$40.07
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$40.62
AVG Volume (30 Days)
8.8K
2.4M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.89
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$44.76
Revenue Next Year
N/A
$35.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.60
$13.88
52 Week High
$13.48
$43.31

Technical Indicators

Market Signals
Indicator
PLBL
TVTX
Relative Strength Index (RSI) 41.54 63.32
Support Level $5.93 $32.62
Resistance Level $9.59 $42.06
Average True Range (ATR) 0.97 2.03
MACD -0.03 0.16
Stochastic Oscillator 27.85 78.40

Price Performance

Historical Comparison
PLBL
TVTX

About PLBL Polibeli Group Ltd Class A Ordinary Shares

Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: